A catalog of genetic loci associated with kidney function from analyses of a million individuals by Wuttke, Matthias et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A catalog of genetic loci associated with kidney function from
analyses of a million individuals
Citation for published version:
Wuttke, M, Li, Y, Li, M, Sieber, KB, Feitosa, MF, Gorski, M, Tin, A, Wang, L, Chu, AY, Hoppmann, A,
Kirsten, H, Giri, A, Chai, JF, Sveinbjornsson, G, Tayo, BO, Nutile, T, Fuchsberger, C, Marten, J, Cocca, M,
Ghasemi, S, Xu, Y, Horn, K, Noce, D, van der Most, PJ, Sedaghat, S, Yu, Z, Akiyama, M, Afaq, S,
Ahluwalia, TS, Almgren, P, Amin, N, Ärnlöv, J, Bakker, SJL, Bansal, N, Baptista, D, Bergmann, S, Biggs ,
ML, Biino, G, Boehnke, M, Boerwinkle, E, Boissel, M, Bottinger, EP, Boutin, T, Brenner, H, Brumat, M,
Campbell, A, Campbell, H, Hayward, C, Joshi, PK, Kerr, S, LifeLines Cohort Study, Lim, S-C, Lind, L,
Lindgren, CM, Liu, J, Liu, J, Loeffler, M, Loos, RJF, Lucae, S, Lukas, MA, Lyytikäinen, L-P, Mägi, R,
Magnusson, PKE, Mahajan, A, Martin, NG, Martins, J, März, W, Mascalzoni, D, Matsuda, K, Meisinger, C,
Meitinger, T, Melander, O, Metspalu, A, Mikaelsdottir, EK, Milaneschi, Y, Miliku, K, Mishra, PP, V. A. Million
Veteran Program, Mohlke, KL, Montgomery, GW, Mychaleckyj, JC, Nadkarni, GN, Nalls, MA, Nauck, M,
Nikus, K, Ning, B, Nolte, IM, Noordam, R, O’Connell, JR, O'Donoghue, ML, Olafsson, I, Oldehinkel, AJ,
Orho-Melander, M, Ouwehand, WH, Padmanabhan, S, Palmer, ND, Palsson, R, Penninx, BWJH, Perls, T,
Perola, M, Pirastu, M, Pirastu, N, Pistis, G, Podgornaia, AI, Polasek, O, Ponte, B, Porteous, DJ, Poulain, T,
Pramstaller, PP, Preuss, MH, Prins, BP, Province, MA, Rabelink, TJ, Raffield, LM, Raitakari, OT, Reilly, DF,
Rettig, R, Rheinberger, M, Rice, KM, Ridker, PM, Rivadeneira, F, Rizzi, F, Roberts, DJ, Robino, A, Rossing,
P, Rudan, I, Rueedi, R, Ruggiero, D, Ryan, KA, Saba, Y, Sabanayagam, C, Salomaa, V, Salvi, E, Saum, K-
U, Schmidt, H, Schmidt, R, Schöttker, B, Schulz, C-A, Schupf, N, Shaffer, CM, Shi, Y, Smith, AV, Smith,
BH, Soranzo, N, Spracklen, CN, Strauch, K, Stringham, HM, Stumvoll, M, Svensson, PO, Szymczak, S, Tai,
E-S, Tajuddin, SM, Tan, NYQ, Taylor, KD, Teren, A, Tham, Y-C, Thiery, J, Thio, CHL, Thomsen, H,
Thorleifsson, G, Toniolo, D, Tönjes, A, Tremblay, J, Tzoulaki, I, Uitterlinden, AG, Vaccargiu, S, van Dam,
RM, van der Harst, P, van Duijn, CM, Velez Edwards, DR, Verweij, N, Vogelezang, S, Völker, U,
Vollenweider, P, Waeber, G, Waldenberger, M, Wallentin, L, Wang, YX, Wang, C, Waterworth, DM, Wei,
WB, White, H, Whitfield, JB, Wild, SH, Wilson, JF, Wojczynski, MK, Wong, C, Wong, T-Y, Xu, L, Yang, Q,
Yasuda, M, Yerges-Armstrong, LM, Zhang, W, Zonderman, AB, Rotter, JI, Bochud, M, Psaty, BM, Vitart, V,
Wilson, JG, Dehghan, A, Parsa, A, Chasman, DI, Ho, K, Morris, AP, Devuyst, O, Akilesh, S, Pendergrass,
SA, Sim, X, Böger, CA, Okada, Y, Edwards, TL, Snieder, H, Stefansson, K, Hung, AM, Heid, IM, Scholz, M,
Teumer, A, Köttgen, A & Pattaro, C 2019, 'A catalog of genetic loci associated with kidney function from
analyses of a million individuals', Nature Genetics, vol. 51, no. 6, pp. 957-972.
https://doi.org/10.1038/s41588-019-0407-x
Digital Object Identifier (DOI):
10.1038/s41588-019-0407-x
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nature Genetics
Publisher Rights Statement:
This is the author’s peer-reviewed manuscript as accepted for publication.
1 
A catalogue of genetic targets for kidney function from analyses of a 1 
million individuals 2 
 3 
Authors for Correspondence: 4 
 5 
Anna Köttgen, MD MPH 6 
Institute of Genetic Epidemiology 7 
Medical Center - University of Freiburg 8 
Hugstetter Str. 49, 79106 Freiburg, Germany 9 
+49 (0)761 270-78050 10 
anna.koettgen@uniklinik-freiburg.de 11 
 12 
Cristian Pattaro PhD 13 
Eurac Research 14 
Institute for Biomedicine 15 
Via Galvani 31, 39100 Bolzano, Italy 16 
+39 0471 055 527 17 
cristian.pattaro@eurac.edu   18 
2 
Abstract 1 
Chronic kidney disease (CKD) is a public health burden with multi-systemic 2 
complications. Through trans-ethnic meta-analysis of genome-wide association studies 3 
of estimated glomerular filtration rate (eGFR) and independent replication (n=1,046,070), 4 
we identified 264 associated loci (166 novel). Of these, 147 were likely to be relevant for 5 
kidney function based on associations with the alternative kidney function marker blood 6 
urea nitrogen (n=416,178). Pathway and enrichment analyses, including mouse models 7 
with renal phenotypes, support the kidney as the main target organ. A genetic risk score 8 
for lower eGFR was associated with clinically diagnosed CKD in 452,264 independent 9 
individuals. Co-localization analyses of associations with eGFR among 783,978 10 
European-ancestry individuals and gene expression across 46 human tissues, including 11 
tubulo-interstitial and glomerular kidney compartments, identified 17 genes differentially 12 
expressed in kidney. Fine-mapping highlighted missense driver variants in 11 genes and 13 
kidney-specific regulatory variants. These results provide a comprehensive priority list of 14 
molecular targets for translational research.  15 
3 
Chronic kidney disease (CKD) is a major public health issue, with increasing incidence 1 
and prevalence worldwide.1 Its associated burden of disease encompasses metabolic 2 
disturbances, end-stage kidney disease, and multi-systemic complications such as 3 
cardiovascular disease.1-4 CKD is a leading cause of death5 and shows one of the highest 4 
increases in disease-attributable mortality over the last decade.2 Nevertheless, public and 5 
clinical awareness remains low.3 Moreover, clinical trials in nephrology are still 6 
underrepresented,6 resulting in scarce therapeutic options to alter disease progression 7 
and high costs for health systems.7 A major barrier to developing new therapeutics is the 8 
limited understanding of the mechanisms underlying kidney function in health and 9 
disease, with consequent lack of therapeutic targets. 10 
Genome-wide association studies (GWAS) and exome-chip studies of the 11 
glomerular filtration rate estimated from serum creatinine (eGFR), the main biomarker to 12 
quantify kidney function and define CKD, have identified nearly one hundred eGFR-13 
associated genetic loci8 in samples of European9-15, Asian16-19, and multiple20 ancestries. 14 
However, similar to other complex traits and diseases, identifying causal genes and 15 
molecular mechanisms implicated by genetic associations is challenging and has only 16 
been successful for few kidney function-associated loci.21,22 Advanced statistical fine-17 
mapping approaches and newly emerging multi-tissue gene expression data provide new 18 
opportunities for prioritizing putative causal variants, effector genes, and target tissues 19 
from results of large-scale GWAS meta-analyses.  20 
We therefore conducted a trans-ethnic GWAS meta-analysis in the CKD Genetics 21 
Consortium (CKDGen, n=765,348), and replicated findings in the Million Veteran Program 22 
(MVP, n=280,722),23 for a combined sample size of >1 million participants. The first aim 23 
of this study was to identify novel, globally important loci for kidney function through 24 
maximizing statistical power (Supplementary Figure 1). Results from GWAS of the 25 
complementary kidney function marker blood urea nitrogen (BUN, n=416,178) were used 26 
to prioritize eGFR-associated loci most likely to be relevant for kidney function. A genetic 27 
risk score (GRS) for low eGFR was used to test relevance for clinically diagnosed CKD 28 
among 452,264 independent individuals. The second aim was to characterize replicated 29 
eGFR-associated loci through complementary computational approaches, including 30 
various enrichment and network analyses, fine-mapping and co-localization with gene 31 
4 
expression in 46 tissues and protein levels (Supplementary Figure 1). We focused this 1 
aim on European ancestry (EA) individuals, as fine-mapping based on summary statistics 2 
requires linkage disequilibrium (LD) reference panels whose sample size should scale 3 
with that of the GWAS.24 The resulting list of prioritized variants and genes provides a rich 4 
resource of potential therapeutic targets to improve CKD treatment and prevention.  5 
 6 
Results  7 
Discovery trans-ethnic meta-analysis  8 
We performed 121 GWAS encompassing 765,348 individuals of European (n=567,460), 9 
East Asian (n=165,726), African American (n=13,842), South Asian (n=13,359), and 10 
Hispanic (n=4,961) ancestries (median age: 54 years; 50% females; Supplementary 11 
Table 1). The median of the study-specific mean eGFR was 89 ml/min/1.73m² 12 
(interquartile range, IQR: 81, 94). GWAS were based on genotypes imputed from the 13 
Haplotype Reference Consortium25 or 1000 Genomes Project26 reference panels 14 
(Methods, Supplementary Table 2). Following study-specific variant filtering and quality 15 
control (QC) procedures, we performed a fixed-effects inverse-variance weighted meta-16 
analysis, showing no evidence of unmodeled population structure (LD Score regression 17 
intercept =1.04; λGC=1.05). After variant filtering, 8,221,591 single nucleotide 18 
polymorphisms (SNPs) were used for downstream analysis (Methods). 19 
We discovered 308 loci containing at least one eGFR-associated SNP at genome-20 
wide significance (Methods), of which 200 were novel and 108 contained an index SNP 21 
reported by previous eGFR GWAS (Figure 1; Supplementary Table 3). Regional 22 
association plots are shown in Supplementary Figure 2. The minor alleles across index 23 
SNPs showed both decreasing and increasing effects on eGFR, with larger effects 24 
observed for lower frequency SNPs (Figure 1, inset). The 308 index SNPs explained 25 
7.1% of the eGFR variance, nearly doubling recent GWAS-based estimates,9 and 19.6% 26 
of eGFR genetic heritability (h2=39%, 95% credible interval: 32%, 47%), estimated in a 27 
participating general-population-based pedigree-study (Supplementary Figure 3; 28 
Methods). Index SNPs’ effects were largely homogeneous across studies (Figure 2A; 29 
5 
Supplementary Table 3) and ancestries (Supplementary Table 4; Supplementary 1 
Material). 2 
 3 
Replication and meta-analysis of >1 million individuals 4 
We assessed replication in an independent trans-ethnic GWAS meta-analysis of eGFR 5 
performed among 280,722 MVP participants.23 Effect estimates, available for 305/308 6 
SNPs, showed almost perfect direction consistency (302/305 SNPs, 99%) and very 7 
strong correlation with the discovery results (Figure 2B). For these 305 SNPs, we 8 
performed a meta-analysis of the 1,046,070 discovery and replication samples. 9 
Replication was met by 262 SNPs (Figure 1; Supplementary Table 3; Methods). Of the 10 
three SNPs not available in MVP, the index SNPs at SHROOM3 (P=3.5×10-120) and 11 
SH3YL1 (P=1.2×10-11) were also considered replicated based on prior evidence15,27, 12 
resulting in a total of 264 replicated SNPs (166 novel). Of these, 74 SNPs were genome-13 
wide significant in MVP alone (Supplementary Table 3).  14 
 15 
Association of eGFR-associated loci with BUN and CKD  16 
To evaluate whether associations with creatinine-based eGFR were likely related to 17 
kidney function or potentially to creatinine metabolism, we assessed the association of 18 
the 264 eGFR-associated index SNPs with BUN, an alternative marker of kidney function 19 
that is inversely correlated with eGFR. Trans-ethnic meta-analysis of 65 BUN GWAS 20 
(n=416,178; Supplementary Table 1) showed no evidence of unmodeled population 21 
structure (λGC=1.03; LD Score regression intercept=0.98) and yielded 111 genome-wide 22 
significant loci (15 known, 96 novel, Supplementary Figure 4, Supplementary Table 23 
5).  24 
Of the 264 replicated eGFR index SNPs, 34 and 146 showed genome-wide and 25 
nominally (P<0.05) significant association with BUN, respectively (Supplementary Table 26 
6). SNP effects were inversely correlated (r=-0.65; Figure 2C). Their relevance to kidney 27 
function was classified as likely for 147 eGFR index SNPs with inverse, significant 28 
associations with BUN (one-sided P<0.05); inconclusive for 102 SNPs not associated 29 
6 
with BUN (P≥0.05); and unlikely for 15 eGFR index SNPs showing concordant, significant 1 
association with BUN (one-sided P<0.05; Supplementary Table 6). This comparative 2 
analysis of complementary biomarkers supports that signals at the majority of eGFR-3 
associated loci likely reflect kidney function. 4 
Next, we investigated the effects of the eGFR index SNPs on CKD in CKDGen 5 
studies (n=625,219, including 64,164 CKD cases; Methods). GWAS meta-analysis of 6 
CKD identified 23 genome-wide significant loci, including 17 likely relevant for kidney 7 
function (SDCCAG8, LARP4B, DCDC1, WDR72, UMOD-PDILT, MYO19, AQP4, 8 
NFATC1, PSD4, HOXD8, NRIP1, SHROOM3, FGF5, SLC34A1, DAB2, UNCX, and 9 
PRKAG2; Supplementary Table 6). The majority of replicated eGFR index SNPs 10 
(224/264) was associated with CKD (one-sided P<0.05; Figure 1, inset), including 130 11 
likely relevant for kidney function (Supplementary Table 6). 12 
Lastly, we tested if a GRS based on the combined effect of the 147 eGFR index 13 
SNPs likely relevant for kidney function was associated with clinically diagnosed CKD and 14 
CKD-related outcomes in the UK Biobank (n=452,264; Methods). A lower GRS, reflecting 15 
a genetically lower eGFR, was associated with higher odds ratios (ORs) of chronic renal 16 
failure, glomerular diseases, acute renal failure, and hypertensive diseases (Figure 2D; 17 
Supplementary Figure 5). The OR of chronic renal failure per 10% lower GRS-predicted 18 
eGFR was 2.13 (95%CI: 1.90, 2.39; P=8.1x10-38). A significant protective association with 19 
urolithiasis may reflect a reduced ability to concentrate urine at lower eGFR.  20 
 21 
Genetic correlations of eGFR and BUN with other phenotypes 22 
We assessed genome-wide genetic correlations (rg) of eGFR associations with each of 23 
748 complex traits and diseases (Methods).28 We observed 37 significant correlations 24 
(P<6.7×10-5=0.05/748, Supplementary Figure 6; Supplementary Table 7). After serum 25 
creatinine, the largest negative correlations were observed between eGFR and serum 26 
citrate (rg=-0.27) and urate (rg=-0.23), followed by anthropometric traits including lean 27 
mass and physical fitness (e.g., rg=-0.20 with left hand grip strength). While the inverse 28 
correlation with muscle mass-related traits likely reflects higher creatinine generation 29 
leading to lower creatinine-based eGFR, the correlations with citrate and urate levels 30 
7 
likely reflect reduced filtration function, as does the positive correlation with GFR 1 
estimated from cystatin C (rg=0.53).  2 
A very similar pattern of genetic correlations was observed for BUN 3 
(Supplementary Table 7), but the genetic correlations with muscle mass-related traits 4 
were generally lower than those for eGFR. The largest genetic correlations of BUN was 5 
observed with CKD (rg=0.47), as compared to creatinine-based (rg=-0.29) and cystatin-6 
based eGFR (rg=-0.26).  7 
In summary, significant genetic correlations with eGFR reflect the two biological 8 
components that govern serum creatinine concentrations: its excretion via the kidney and 9 
its generation in muscle. The fact that genetic correlations between BUN and muscle-10 
mass related traits are generally lower than those observed for eGFR underscores the 11 
value of genetic associations with BUN to help prioritize eGFR-associated loci most likely 12 
to be relevant for kidney function. 13 
 14 
Functional enrichment and pathway analyses 15 
To identify molecular mechanisms and tissues of importance for kidney function, we 16 
assessed the enrichment of the eGFR and BUN genetic associations using tissue-specific 17 
gene expression, regulatory annotations, and gene sets and pathways (Methods). First, 18 
we used eGFR-associated SNPs (P<5×10-8) to explore enriched pathways, tissues and 19 
cell types based on gene expression data using DEPICT.29 We identified 16 significantly 20 
enriched physiological systems, cell types and tissues highlighting several aspects of 21 
kidney function, physiology and disease. The strongest enrichment was observed for 22 
urogenital and renal physiological systems and tissues (kidney, kidney cortex, and urinary 23 
tract; false discovery rate (FDR) <0.05; Supplementary Figure 7A and B). Pathway and 24 
gene set enrichment analysis identified three highly correlated and strongly associated 25 
meta gene-sets (P<1×10-6, FDR<0.05), including some relevant to kidney such as 26 
polyuria, dilated renal tubules, and expanded mesangial matrix, as well as signaling and 27 
transcription, and energy metabolism (Supplementary Figure 7C). Tissue and cell-type 28 
enrichment analysis of BUN-associated SNPs with P<5×10-8 highlighted a very similar 29 
8 
pattern (Supplementary Figure 8) but without enrichment for muscle tissues, further 1 
supporting the use of BUN to prioritize loci most likely to be related to kidney function. 2 
Second, we used stratified LD Score regression30 on the genome-wide eGFR and 3 
BUN summary statistics to identify cell-type groups with enriched heritability based on 4 
data from diverse, cell-type specific functional genomic elements. The strongest 5 
enrichment for eGFR was observed for kidney (13.2-fold), followed by liver (7.3-fold) and 6 
adrenal/pancreas (5.7-fold enrichment; Supplementary Table 8). Kidney was also the 7 
most enriched cell-type group for BUN (11.5-fold enrichment; Supplementary Table 8).  8 
Lastly, using a complementary approach, we assessed enrichment of eGFR-9 
associated variants in genes resulting in kidney phenotypes in genetically manipulated 10 
mice.31 From the Mouse Genome Informatics database, we selected all genes causing 11 
abnormal GFR (n=24), abnormal kidney physiology (n=453), or abnormal kidney 12 
morphology (n=764), and interrogated their human orthologs in the eGFR summary 13 
statistics (Methods). We identified significant associations in 10 genes causing abnormal 14 
GFR in mice (enrichment p-value=8.9×10-4), 55 causing abnormal kidney physiology 15 
(enrichment p-value=1.1×10-4) and 96 causing abnormal kidney morphology (enrichment 16 
p-value=1.8×10-5; Figure 3; Methods). Of these, 25 genes represent novel eGFR 17 
candidate genes in humans, i.e. they were not previously reported to contain genome-18 
wide significant eGFR-associated SNPs or map near known loci (Supplementary Table 19 
9). The existing mouse models may pave the way for experimental confirmation of these 20 
findings. 21 
 22 
Fine-mapping and second signal analysis in EA individuals 23 
Conditional and fine-mapping analyses were restricted to EA participants, for whom data 24 
to construct a large enough LD reference panel was publicly available (Methods). The 25 
meta-analysis of 85 EA CKDGen GWAS identified 256 genome-wide significant loci 26 
(Supplementary Table 10). Replication among 216,518 EA MVP participants confirmed 27 
228 SNPs, including 227 index SNPs that met replication criteria and the SHROOM3 28 
index SNP (Methods, Supplementary Table 10). Of these 228 SNPs, 221 mapped into 29 
one of the 264 replicated loci from the trans-ethnic analysis (≤±500 kb from the trans-30 
9 
ethnic index SNP), and the remaining 7 showed P≤3.3×10-6 in the trans-ethnic discovery 1 
analysis. BUN GWAS meta-analysis of CKDGen EA studies (n=243,029) allowed to 2 
classify 122 SNPs as likely relevant for kidney function, 90 as inconclusive, and 16 as 3 
unlikely (Supplementary Table 10).  4 
To perform statistical fine-mapping of the 228 eGFR loci, we first performed 5 
summary-statistics based conditional analysis and identified 253 independent genome-6 
wide significant SNPs (Supplementary Table 11) mapping into 189 regions (Methods). 7 
For each independent variant, we computed a 99% credible set,32 with median set size 8 
of 26 SNPs (IQR: 6, 60). We observed 58 small credible sets (≤5 SNPs), including 20 9 
single-SNP sets: EDEM3, CACNA1S, HOXD11, CPS1, DAB2, SLC34A1, LINC01512, 10 
LARP4B, DCDC1, SLC25A45, SLC6A13, GATM, CGNL1, CYP1A1, NRG4, RPL3L, 11 
UMOD-PDILT, SLC47A1, and two independent sets at BCL2L14 (Supplementary Table 12 
11; Figure 4). Of the 58 small credible sets, 33 were likely relevant for kidney function 13 
and contain genes and SNPs that can now be prioritized for further study 14 
(Supplementary Table 11). 15 
Credible set SNPs were annotated with respect to their functional consequence 16 
and regulatory potential. Missense SNPs with >50% posterior probability (PP) of driving 17 
the association and/or mapping into a small credible set are of particular interest because 18 
they directly implicate the affected gene. Such missense SNPs were identified in 11 19 
genes (SLC47A1, RPL3L, SLC25A45, CACNA1S, EDEM3, CPS1, KLHDC7A, PPM1J, 20 
CERS2, C9, and SLC22A2; Supplementary Table 12), of which CACNA1S, RPL3L, 21 
CERS2, and C9 were likely relevant for kidney function (Figure 4A). The majority of the 22 
11 variants had CADD score>15, indicating potential deleteriousness.33 Several identified 23 
genes are plausible biological candidates for driving the association signal (Table 1). For 24 
example, the missense p.(Ala465Val) SNP in SLC47A1 (PP>99%) alters the encoded 25 
multidrug and toxin extrusion protein (MATE1), a transport protein responsible for the 26 
secretion of cationic drugs, toxins and internal metabolites including creatinine across 27 
brush border membranes including kidney proximal tubules. The fact that MATE1 28 
knockout mice have higher blood levels of both creatinine and BUN34 argues against a 29 
sole effect on creatinine transport.  30 
10 
 To evaluate the regulatory potential of small credible set SNPs in kidney, we 1 
annotated them to open chromatin regions identified from primary human tubular and 2 
glomerular cell cultures,35 as well as from publicly available kidney cells types (Methods). 3 
We identified 72 SNPs mapping into one of these annotations, which may thus represent 4 
causal regulatory variants (Supplementary Table 12). A particularly interesting finding 5 
was the intronic rs77924615 in PDILT, which showed PP>99% of driving the association 6 
at the UMOD locus, and mapped into open chromatin in all evaluated resources (native 7 
kidney cells, ENCODE and Roadmap kidney cell types; Figure 4B).  8 
 9 
Gene prioritization: co-localization with gene expression  10 
We performed co-localization analyses for each eGFR-associated locus with gene 11 
expression in cis across 46 tissues including kidney glomerular and tubulo-interstitial 12 
compartments (Methods). A PP>80% of co-localization in at least one kidney tissue was 13 
observed for 17 transcripts mapping into 16 of the 228 replicated loci (Figure 5), pointing 14 
towards a shared underlying SNP associated with both eGFR and gene expression, and 15 
implicating the gene encoding the co-localized transcript as the locus’ effector gene(s).  16 
Novel insights emerged on several levels: first, UMOD is a well-established causal 17 
gene for CKD and can therefore be used to evaluate our workflow. In the tubulo-interstitial 18 
compartment, we observed a shared underlying variant associated with higher UMOD 19 
gene expression and lower eGFR (Figure 5), consistent with previous GWAS of urinary 20 
uromodulin concentration, in which alleles associated with lower eGFR at UMOD15 were 21 
associated with higher urinary uromodulin concentrations.36 The lead SNP at this locus 22 
was rs77924615, highlighted above as the candidate causal regulatory variant mapping 23 
into the intron of PDILT (upstream of UMOD). The association with differential UMOD but 24 
not PDILT gene expression supports UMOD as the causal gene and rs77924615 as a 25 
regulatory SNP.  26 
Second, novel, biologically plausible candidates emerged. For example, our 27 
results suggest KNG1 and FGF5 as effector genes in the respective eGFR-associated 28 
loci (Figure 5, Supplementary Table 13). KNG1 encodes for high-molecular weight 29 
kininogen, which is cleaved to bradykinin. Bradykinin influences blood pressure, 30 
11 
natriuresis and diuresis, and can be linked to kidney function via the renin-angiotensin-1 
aldosterone system.37 FGF5 encodes for Fibroblast Growth Factor 5, and the index SNPs 2 
for eGFR or highly correlated SNPs (r2>0.9) have been identified in multiple GWAS of 3 
blood pressure, atrial fibrillation, coronary artery disease, hematocrit and multiple kidney-4 
function related traits (Supplementary Table 13). The eGFR index SNP rs1458038 5 
(PP>50%, CADD score=14.8; Supplementary Table 13), co-localized with the eGFR 6 
signal only in tubulo-interstitial kidney portions (Figure 5), supporting its regulatory 7 
potential on the expression levels of FGF5 in this compartment. Both KNG1 and FGF5 8 
index SNPs were associated with BUN and CKD, and are thus likely related to kidney 9 
function. 10 
Third, co-localization of eGFR with gene expression across multiple tissues 11 
revealed that for kidney-co-localized transcripts, some showed the same direction on 12 
transcript levels across all tissues with lower eGFR (e.g. METTL10), while others showed 13 
higher transcript levels in some tissues but lower levels in others (e.g. SH3YL1; Figure 14 
5). These observations were also reflected broadly across all transcripts with evidence of 15 
co-localization in any tissue (Supplementary Figure 9), and highlight tissue-shared and 16 
tissue-specific signals.38,39 17 
Finally, trans-eQTL annotation of the index SNPs in whole and peripheral blood 18 
identified a reproducible link of rs10774625 (12q24.11) with several transcripts (Methods; 19 
Supplementary Material; Supplementary Tables 14 and 15). 20 
 21 
Co-localization with uromodulin protein levels in urine  22 
The UMOD locus is of particular clinical interest for CKD research:21 rare UMOD 23 
mutations cause autosomal-dominant tubulo-interstitial kidney disease40, and common 24 
variants at UMOD give rise to the strongest eGFR and CKD GWAS signals.15 We 25 
therefore performed conditional analyses based on the EA-specific summary statistics 26 
and found two independent variants: rs77924615, mapping into upstream PDILT, and 27 
rs34882080 mapping into an intron of UMOD (Figure 6A). SNP association with the 28 
urinary uromodulin-to-creatinine ratio (UUCR) in one participating cohort (Figure 6B) 29 
matched the eGFR association pattern. Co-localization of the conditional eGFR and 30 
12 
UUCR associations was evaluated separately for the rs34882080 (Figure 6C) and 1 
rs77924615 (Figure 6D). Both regions showed high probability of a shared underlying 2 
variant driving the respective associations with eGFR and UUCR levels (PP=0.97 and 3 
0.96, respectively), further supporting rs77924615 as a causal regulatory variant and 4 
UMOD as its effector gene.  5 
 6 
A summary of the various gene characterization results for replicated loci from the EA 7 
analysis is shown in Supplementary Table 16, to facilitate selection of the most 8 
promising candidates for further experimental studies.  9 
 10 
Discussion  11 
This trans-ethnic study is 5-fold larger than previous eGFR GWAS meta-analyses and 12 
identified 264 replicated loci, 166 of which are reported here for the first time. By also 13 
analyzing BUN, an established complementary kidney function marker, we highlight 14 
eGFR-associated loci that are likely to be important for kidney function as opposed to 15 
creatinine metabolism, and provide a comprehensive annotation resource. Clinical 16 
relevance is supported by associations of a GRS for low eGFR with higher odds of 17 
clinically diagnosed CKD, CKD-related phenotypes, and hypertension. Enrichment 18 
analyses confirm the kidney as the main target organ. Co-localization of associations with 19 
eGFR and gene expression in the kidney implicates specific target genes for follow-up. 20 
Conditional analyses, fine-mapping and functional annotation at 228 replicated eGFR-21 
associated loci among EA participants implicate single potentially causal variants at 20 22 
loci.  23 
 Most previous eGFR GWAS meta-analyses were limited to a single ancestry 24 
group8 and did not prioritize causal variants or effector genes in associated loci. While 25 
underpowered to uncover novel loci, one previous trans-ethnic study employed fine-26 
mapping, resolving one signal to a single variant,20 rs77924615 at UMOD-PDILT, also 27 
identified in our study. At this locus, we further characterized the relationship between the 28 
causal variant, UMOD expression in the target tissue, and uromodulin protein levels. This 29 
increase in resolution - from locus to single potentially causal variant with its effector gene, 30 
13 
protein and target tissue, represents a critical advance over 10 years of eGFR GWAS,15 1 
and is a prerequisite for translational research. 2 
The complementary multi-tissue approaches including enrichment analyses based 3 
on gene expression, regulatory annotations, and gene-sets and pathways highlight the 4 
kidney as the most important target organ. However, relatively few kidney-specific 5 
experimental datasets are publicly available. For example, the kidney is not well 6 
represented in the GTEx Project and not included in its tissue-specific eQTL datasets,38 7 
which emphasizes the value of open access resources and in depth characterization of 8 
uncommon tissues and cell types. We were able to specifically investigate the kidney by 9 
using a recently published eQTL dataset from glomerular and tubulo-interstitial portions 10 
of micro-dissected human kidney biopsies,41 kidney-specific regulatory information from 11 
the ENCODE and Roadmap resources, and by obtaining regulatory information from 12 
primary cultures of human glomerular and tubulo-interstitial cells.35 13 
Functional follow-up studies of potentially causal variants will benefit from 14 
prioritized loci that show clear evidence supporting one or a few SNPs driving the 15 
association signal. The fine-mapping workflow allowed us to prioritize several SNPs at 16 
single- or ≤5-SNP resolution, some of which may have broader clinical relevance. For 17 
example, the OCT2 protein encoded by SLC22A2 transports several cationic drugs such 18 
as metoprolol, cisplatin, metformin and cimetidine across the basolateral membrane of 19 
renal tubular cells.42 The prioritized missense SNP encodes p.(Ser270Ala), a known 20 
pharmaco-genomic variant that alters the transport of these drugs and their side-effects, 21 
such as cisplatin-induced nephrotoxicity.43 Along the same lines, the prioritized SNP 22 
encoding the p.(Ala465Val) substitution in the transporter MATE1 encoded by SLC47A1 23 
may affect the ability to secrete drugs and other toxins from proximal tubular cells into the 24 
urine44 and hence alter CKD risk. 25 
 Strengths of this project include the large sample size with dense genotype 26 
imputation, standardized and automated phenotype generation and QC, independent 27 
replication, as well as advanced and comprehensive downstream bioinformatics 28 
analyses. Further strengths are the use of BUN to prioritize eGFR-associated loci likely 29 
relevant for kidney function, and to provide genome-wide BUN summary statistics as a 30 
14 
annotation resource for other studies of eGFR. Moreover, we evaluated a GRS for eGFR 1 
for association with clinically diagnosed CKD in a large independent study. Among the 2 
limitations, non-European populations are still underrepresented in our study, like many 3 
other genomic efforts.45 Statistical fine-mapping using trans-ethnic data with different LD 4 
structures can potentially narrow down association signals. However, a sufficiently large 5 
reference dataset to compute ancestry-matched LD structure for summary-statistics 6 
based fine-mapping was only available for EA, highlighting the potential of future large-7 
scale efforts with trans-ethnic fine-mapping and the need to generate data from non-EA 8 
populations enabling such endeavors. Lastly, several SNPs had small effective sample 9 
sizes in some subpopulations, which might have affected the ability to assess between-10 
ancestry heterogeneity and potentially underestimated true heterogeneity.  11 
We estimated GFR from serum creatinine, as done in clinical practice and 12 
observational studies, because direct measurement of kidney function is invasive, time-13 
consuming, and burdensome. Under the assumption that genetic associations supported 14 
by multiple markers are less likely to reflect marker metabolism, we used BUN to prioritize 15 
eGFR-loci likely to be relevant to kidney function. Blood creatinine, urea and cystatin C 16 
concentrations are influenced not only by glomerular filtration, but also by their synthesis, 17 
active secretion, or reabsorption, as illustrated by loci detected in our study: for example, 18 
the GATM locus was associated with eGFR but not with BUN, consistent with the function 19 
of the encoded protein as a rate-limiting enzyme in creatine synthesis.46 Conversely, the 20 
SLC14A2 locus was associated with BUN but not with eGFR, consistent with the function 21 
of the encoded protein as a urea transporter.47 Even so, lack of a SNP’s association with 22 
one kidney function marker based on a combination of p-value and effect direction may 23 
not necessarily mean that the locus is not relevant to kidney function. Our categorization 24 
of the eGFR loci into three classes based on effect direction and significance of the BUN 25 
associations should be interpreted with caution, with “likely” and “unlikely” reflecting 26 
uncertainty of the assignment. Factors complicating the comparison of eGFR and BUN 27 
associations at the locus level are differential statistical power, differential ancestry 28 
distribution, and potential allelic heterogeneity. Further large-scale studies with multiple 29 
kidney function markers measured in the same individuals are therefore warranted.  30 
15 
To identify broadly representative and generalizable association signals, we 1 
focused on SNPs that were present in the majority of the participating studies. This choice 2 
might have limited our ability to uncover novel or to fine-map low-frequency or population-3 
specific variants, which represents a complementary avenue of research. Moreover, even 4 
with well-powered fine-mapping approaches, potentially causal SNPs need to be 5 
confirmed as functional variants in experimental studies. Although co-localization with 6 
gene expression can help prioritize effector genes, these associations are based on 7 
measures from a single time point and hence cannot answer whether changes in gene 8 
expression precede or follow changes in kidney function.  9 
In summary, we identified and characterized a large number of loci associated with 10 
eGFR and prioritized potential effector genes, driver variants and target tissues. These 11 
findings will help direct functional studies and advance the understanding of kidney 12 
function biology, a prerequisite to develop novel therapies to reduce the burden of CKD.  13 
16 
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Online Methods 1 
Overview 2 
We set up a collaborative meta-analysis based on a distributive data model and QC 3 
procedures. To maximize phenotype standardization across studies, an analysis plan and 4 
a command line script (https://github.com/genepi-freiburg/ckdgen-pheno) were created 5 
centrally and provided to all participating studies (mostly population-based, 6 
Supplementary Table 1). Data processing, analysis and troubleshooting instructions 7 
were distributed to all studies via a Wiki system 8 
(https://ckdgen.eurac.edu/mediawiki/index.php/ 9 
CKDGen_Round_4_EPACTS_analysis_plan). Automatically generated summary files 10 
were checked centrally. Upon phenotype approval, studies run their GWAS and uploaded 11 
results and imputation quality (IQ) information to a common calculation server. GWAS 12 
QC was performed using GWAtoolbox48 and custom scripts to assess ancestry-matched 13 
allele frequencies and variant positions. All studies had their own research protocols 14 
approved by the respective local ethics committees. All participants in all studies provided 15 
written informed consent.  16 
 17 
Phenotype definition 18 
Each study measured serum creatinine and BUN as described in Supplementary Table 19 
1. Creatinine values obtained with a Jaffé assay before 2009 were calibrated by 20 
multiplying by 0.95.49 Studies on >18 year-old adults estimated GFR with the Chronic 21 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation,50 using the R package 22 
‘nephro’.51 Studies on ≤18 year-old individuals used the Schwartz formula.52 eGFR was 23 
winsorized at 15 and 200 ml/min/1.73m2. CKD was defined as eGFR<60 ml/min/1.73m2. 24 
In studies reporting blood urea measurements, BUN was derived as blood urea×2.8, with 25 
units expressed as mg/dl.  26 
20 
Genotyping and genotype imputation 1 
Genotypes imputed based on the Haplotype Reference Consortium (HRC) v1.1 or the 2 
1000 Genomes Project phase 3 v5 (1000Gp3v5) ALL or phase 1 v3 (1000Gp1v3) ALL 3 
panels. Imputed variants were coded as allelic dosages accompanied by the 4 
corresponding IQ scores (IMPUTE2 info score, MACH/minimac RSQ, or as applicable), 5 
and annotated on the NCBI b37 (hg19) reference build (see Supplementary Table 2 for 6 
study-specific genotyping arrays, haplotype phasing and genotype imputation methods). 7 
 8 
Genome-wide association studies (GWAS) 9 
Each study fitted sex- and age-adjusted linear regression models to log(eGFR) and BUN. 10 
Regression residuals were regressed on SNP dosage levels, assuming an additive 11 
genetic model. Study site, genetic principal components (PCs), relatedness, or other 12 
study-specific features, were accounted for in the study-specific models as appropriate 13 
(Supplementary Table 2). Logistic regression models were fitted for CKD. 14 
 15 
Trans-ethnic GWAS meta-analysis  16 
Studies contributed 121 GWAS summary statistics files for eGFR (total post-QC 17 
n=765,348), 60 GWAS files for CKD (total post-QC n=625,219, including 64,164 CKD 18 
cases), and 65 GWAS files for BUN (total post-QC n=416,178). Ancestry-specific details 19 
for eGFR, CKD and BUN are given in Supplementary Table 1. 20 
Before meta-analysis, study-specific GWAS files were filtered to retain only 21 
variants with IQ score>0.6 and minor allele count (MAC)>10, and genomic control (GC) 22 
correction applied in case of GC factor λGC>1. Fixed effects inverse-variance weighted 23 
meta-analysis was performed using METAL,53 which was adapted to increase the 24 
precision of effect estimates and their standard errors (SE; seven decimal places instead 25 
of four). 26 
After meta-analysis of 43,994,957 SNPs, only SNPs present in ≥50% of the GWAS 27 
files and with total MAC≥400 were retained. Across ancestries, this yielded 8,221,591 28 
variants for eGFR (8,834,748 in EA), 8,176,554 for BUN (8,358,347 in EA), and 9,585,923 29 
21 
for CKD. Post-meta-analysis GC correction was not applied (LD Score regression 1 
intercept≈1 in all analyses of eGFR, BUN, and CKD).54 The genome-wide significance 2 
level was set at 5×10-8. Between-study heterogeneity was assessed using the I2 3 
statistic.55 For CKD, variants with I2≥95% were removed to moderate influence of single 4 
large studies. Variants were assigned to loci by selecting the SNP with the lowest p-value 5 
genome-wide as the index SNP, defining the corresponding locus as the 1 Mb-segment 6 
centered on the index SNP, and repeating the procedure until no further genome-wide 7 
significant SNPs remained. The extended MHC region was considered as a single locus. 8 
A locus was considered novel if not containing any variant identified by previous GWAS 9 
of eGFR. 10 
 11 
Meta-regression analysis of trans-ethnic GWAS 12 
For eGFR, we evaluated ancestry-related heterogeneity using the software Meta-13 
Regression of Multi-Ethnic Genetic Association (MR-MEGA v0.1.2)56 using study-specific 14 
GWAS results. Meta-regression models included three axes of genetic variation. GC 15 
correction was applied to the meta-regression results. The 308 genome-wide significant 16 
index SNPs from the trans-ethnic GWAS meta-analysis were tested for ancestry-related 17 
heterogeneity of the allelic effects at a significance level of 0.05/308=1.6×10-4 (referring 18 
to the corresponding p-value as p-anc-het). 19 
 20 
Variance explained and genetic heritability 21 
The proportion of phenotypic variance explained by the index SNPs was estimated as 22 
𝛽2 (
2𝑝(1−𝑝)
𝑣𝑎𝑟
), with β being the SNP effect, p the effect allele frequency, and var the 23 
variance of the sex- and age-adjusted log(eGFR) residuals (assumed as 0.016 based on 24 
data from 11,827 EA participants of the population-based ARIC study).9 Genetic 25 
heritability of age- and sex-adjusted log(eGFR) was estimated using the R package 26 
‘MCMCglmm’57 on the Cooperative Health Research In South Tyrol (CHRIS) study,58 a 27 
participating pedigree-based study with 186 up-to-5 generation pedigrees (n=4373).59 We 28 
22 
fitted two models, with and without the inclusion of the identified index SNPs (304/308), 1 
running 1,000,000 MCMC iterations (burn in=500,000).59 2 
 3 
Comparison with and replication of results in the MVP  4 
The eGFR-associated SNPs identified in the discovery GWAS meta-analyses, were 5 
tested for replication in a GWAS from the MVP,23 an independent trans-ethnic study with 6 
participants recruited across 63 U.S. Veteran’s Administration (VA) medical facilities. 7 
Written informed consent was obtained and all documents and protocols were approved 8 
by the VA Central Institutional Review Board. After genotyping and QC, genotypes were 9 
phased and imputed on the 1000Gp3v5 reference panel. Serum creatinine was assessed 10 
up to one year prior to MVP enrollment using isotope dilution mass spectrometry. GFR 11 
was estimated using the CKD-EPI equation50 after excluding subjects on dialysis, 12 
transplant patients, amputees, individuals on HIV medications, and those with creatinine 13 
values of <0.4 mg/dl. GWAS of eGFR on SNP dosage levels were performed by fitting 14 
linear regression models adjusted for age at creatinine measurement, age2, sex, body 15 
mass index, and the first 10 genetic PCs, using SNPTEST v2.5.4-beta.60 All GWAS were 16 
stratified by self-reported ethnicity (79.6% White non-Hispanic; 20.4% Black non-17 
Hispanic), diabetes, and hypertension status. Results were combined across strata using 18 
fixed effects inverse-variance weighted meta-analysis in METAL.53 This analysis 19 
encompassed a total of 280,722 individuals across all strata, of whom 216,518 were non-20 
Hispanic Whites (EA). The MVP is described more extensively in the Supplementary 21 
Material. 22 
Of the 308 eGFR index SNPs identified in the CKDGen trans-ethnic analysis, 305 23 
variants or their good proxies were available in the MVP GWAS (proxies had to have 24 
r2≥0.8 with the index SNP and were selected by maximum r2 followed by minimum 25 
distance in case of ties). Replication testing of the 256 EA-specific index SNPs was 26 
restricted to the MVP EA GWAS. CKDGen and MVP meta-analysis results were pooled 27 
via sample size weighted meta-analysis of z-scores using METAL.53 In both the trans-28 
ethnic and EA-specific analyses, replication was defined as a one-sided p-value<0.05 in 29 
the MVP and genome-wide significance of the CKDGen and MVP meta-analysis result. 30 
23 
Assessment of kidney function relevance using BUN 1 
We used genetic associations with BUN to assess replicated eGFR-associated SNPs 2 
with respect to their potential kidney function relevance. Support for kidney function 3 
relevance was categorized as “likely” (1) for all eGFR index SNPs with an inverse, 4 
significant (one-sided P<0.05) association with BUN for a given reference allele, 5 
“inconclusive” (2) for eGFR index SNPs whose effect on BUN was not different from 0 6 
(P≥0.05), and “unlikely” (3) for all eGFR index SNPs with a concordant, significant (one-7 
sided P<0.05) association with BUN for a given reference allele. 8 
 9 
Genetic risk score (GRS) analysis in the UK Biobank dataset 10 
To test the combined effect of eGFR-associated SNPs on clinically diagnosed CKD 11 
related outcomes, a GRS-based association analysis was conducted based on summary 12 
GWAS results, as described before.61,62 The genetic association results with the diseases 13 
were obtained for 452,264 UK Biobank participants available in the GeneAtlas63 database 14 
for glomerular diseases (ICD-10 codes N00-N08; 2289 cases); acute renal failure (N17; 15 
4913 cases); chronic renal failure (N18; 4905 cases); urolithiasis (N20-N23; 7053 cases); 16 
hypertensive diseases (I10-I15; 84,910 cases); and ischemic heart diseases (I20-I25; 17 
33,387 cases). Asthma (J45; 28,628 cases) was included as a negative control. The 18 
log(estimated OR) provided by the GeneAtlas phewas interface was used as effect size, 19 
and its SE was calculated from the corresponding effect size and p-value. When OR=1, 20 
the SE was imputed by the median value of the remaining associations of the trait. Of the 21 
147 eGFR index SNPs from the trans-ethnic GWAS meta-analysis that were replicated 22 
and showed likely kidney function relevance, 144 were available in the UK Biobank 23 
dataset, and 259 out of all 264 replicated trans-ethnic GWAS meta-analysis SNPs. The 24 
effect beta of the GRS association corresponds to the OR of the disease depending on 25 
the relative change in eGFR, e.g. OR=1.10beta for a 10% change in eGFR. Alternatively, 26 
exp(beta) can be interpreted as the OR of the disease per unit change of log(eGFR).   27 
24 
Genetic correlations with other complex traits and diseases  1 
Genome-wide genetic correlation analysis was performed to investigate evidence of co-2 
regulation or shared genetic bases between eGFR and BUN and other complex traits and 3 
diseases, both known and not known to correlate with eGFR and BUN. We estimated 4 
pairwise genetic correlation coefficients (rg) between the results of our trans-ethnic meta-5 
analyses of eGFR and BUN and each of 748 pre-computed and publicly available GWAS 6 
summary statistics of complex traits and diseases available through LD Hub v1.9.0 using 7 
LD Score regression.28 An overview of the sources of these summary statistics and their 8 
corresponding sample sizes is available at http://ldsc.broadinstitute.org. Statistical 9 
significance was assessed at the Bonferroni corrected level of 0.05/748=6.7×10-5. 10 
 11 
Pathway and tissue enrichment analysis 12 
We used DEPICT v1 release 194 to perform Data-Driven Expression Prioritized 13 
Integration for Complex Traits analysis,29 including pathway/gene-set enrichment and 14 
tissue/cell type analyses as described previously.9,10 All 14,461 gene sets were 15 
reconstituted by identifying genes that were transcriptionally co-regulated with other 16 
genes in a panel of 77,840 gene expression microarrays,64 from mouse knock-out studies, 17 
and molecular pathways from protein-protein interaction screening. In the tissues and cell 18 
type enrichment analysis, we tested whether genes in associated regions were highly 19 
expressed in 209 MeSH annotation categories for 37,427 microarrays (Affymetrix U133 20 
Plus 2.0 Array platform). For both eGFR and BUN, we included all variants associated 21 
with the trait at P<5×10-8 in the trans-ethnic meta-analysis. Independent variant clumping 22 
was performed using Plink 1.965 with 500 kb flanking regions and r²>0.01 in the 23 
1000Gp1v3 dataset. After excluding the MHC region, DEPICT was run with 500 24 
repetitions to estimate the FDR and 5000 permutations to compute p-values adjusted for 25 
gene length by using 500 null GWAS. All significant gene sets were merged into meta 26 
gene sets by running an affinity propagation algorithm66 implemented in the Python ‘scikit-27 
learn’ package (http://scikit-learn.org/). The resulting network was visualized using 28 
Cytoscape (http://cytoscape.org/). 29 
Enrichment of heritability by cell type group  30 
25 
We used stratified LD Score regression to investigate important tissues and cell types 1 
based on the trans-ethnic eGFR and BUN meta-analysis results. Heritability enrichment 2 
in 10 cell type groups was assessed using the default options of stratified LD Score 3 
regression described previously.30 The 10 cell type groups were collapsed from 220 cell-4 
type specific regulatory annotations for the four histone marks H3K4me1, H3K4me3, 5 
H3K9ac, and H3K27ac. The enrichment of a cell type category was defined as the 6 
proportion of SNP heritability in that group divided by the proportion of SNPs in the same 7 
cell type group. 8 
 9 
Analysis of genes causing kidney phenotypes in mice  10 
A nested candidate gene analysis was performed using GenToS67 to identify additional 11 
genetic associations that were not genome-wide significant. Candidate genes that when 12 
manipulated cause kidney phenotypes in mice were selected using the comprehensive 13 
Mouse Genome Informatics (MGI) phenotype ontology in September 2017 (abnormal 14 
renal glomerular filtration rate [MP:0002847]; abnormal kidney morphology 15 
[MP:0002135]; abnormal kidney physiology [MP:0002136]). The human orthologs of 16 
these genes were obtained, when available, using the Human-Mouse: Disease 17 
Connection webtool (http://www.informatics.jax.org/humanDisease.html). Statistical 18 
significance was defined as a Bonferroni correction of a type I error level of 0.05 for the 19 
number of independent common SNPs across all genes in each of the three candidate 20 
gene lists plus their flanking regions, derived from an ancestry-matched reference 21 
population. The GWAS meta-analysis summary statistics for eGFR were queried for 22 
significantly associated SNPs mapping into the selected candidate genes. Enrichment of 23 
significant genetic associations in genes within each candidate list was computed from 24 
the complementary cumulative binomial distribution.67 GenToS was used with default 25 
parameters on each of the three candidate gene lists, using the 1000 Genomes phase 3 26 
release 2 ALL dataset as reference.  27 
 28 
 29 
26 
Independent variant identification in the EA meta-analysis 1 
To identify additional, independent eGFR-associated variants within the EA-specific and 2 
replicated loci, approximate conditional analyses were performed based on genome-wide 3 
discovery summary statistics that incorporated LD information from an ancestry-matched 4 
reference population. These analyses were restricted to participants of EA, because an 5 
LD reference sample scaled to the size of our meta-analysis could only be constructed 6 
from publicly available data for EA individuals,24 for which we randomly selected 15,000 7 
UK Biobank participants (dataset ID 8974). Individuals who withdrew consent and those 8 
not meeting data cleaning requirements were excluded, keeping only those who passed 9 
sex-consistency check, had ≥95% call rate, and did not represent outliers with respect to 10 
SNP heterozygosity. For each pair of individuals, the proportion of variants shared 11 
identical-by-descent (IBD) was computed using PLINK.68 Only one member of each pair 12 
with IBD coefficient ≥0.1875 was retained. Individuals were restricted to those of EA by 13 
excluding outliers along the first two PCs from a PC analysis seeded with the HapMap 14 
phase 3 release 2 populations as reference. The final dataset to estimate LD included 15 
13,558 EA individuals and 16,969,363 SNPs.  16 
The basis for statistical fine-mapping were the 228 1-Mb genome-wide significant 17 
loci identified in the EA meta-analysis, clipping at chromosome borders. Overlapping loci 18 
as well as pairs of loci whose respective index SNPs were correlated (r² >0.1 in the UKBB 19 
LD dataset described above) were merged. A single SNP was chosen to represent the 20 
MHC region, resulting in a final list of 189 regions prior to fine-mapping. Within each 21 
region, the GCTA COJO Slct algorithm69 was used to identify independent variants 22 
employing a step-wise forward selection approach. We used the default collinearity cut-23 
off of 0.9 (sensitivity analyses showing no major influence of alternative cutoff values; 24 
data not shown). We deemed an additional SNP as independently genome-wide 25 
significant if the SNPs’ p-value conditional on all previously identified SNPs in the same 26 
region was <5×10-8.   27 
27 
Fine-mapping and credible sets in the EA meta-analysis 1 
For each region containing multiple independent SNPs and for each independent SNP in 2 
such regions, approximate conditional analyses were conducted using the GCTA COJO-3 
Cond algorithm to generate approximate conditional association statistics conditioned on 4 
the other independent SNPs in the region. Using the Wakefield’s formula implemented in 5 
the R package ’gtx’,70 we derived approximate Bayes factors (ABF) from conditional 6 
estimates in regions with multiple independent SNPs and from the original estimates for 7 
regions with a single independent SNP. Given that 95% of the SNP effects on log(eGFR) 8 
fell within -0.01 to 0.01, the standard deviation prior was chosen as 0.0051 based on 9 
formula 8 in the original publication.32 Sensitivity analyses showed that results were 10 
robust when higher values were used for the standard deviation prior (data not shown). 11 
For each variant within an evaluated region, the ABF obtained from the association betas 12 
and their SEs of the marginal (single signal region) or conditional estimates (multi-signal 13 
regions) was used to calculate the PP for a SNP of driving the association signal (“causal 14 
variant”). We derived 99% credible sets, representing the SNP sets containing the 15 
variant(s) driving the association signal with 99% probability, by ranking variants by their 16 
PP and adding them to the set until reaching a cumulative PP>99% in each region.  17 
 18 
Variant annotation 19 
Functional annotation of SNPs mapping into credible sets was performed with SNiPA v3.2 20 
(March 2017),71 based on the 1000Gp3v5 and Ensembl v87 datasets. SNiPA was also 21 
used to derive the Combined Annotation Dependent Depletion (CADD) PHRED-like 22 
score,72 based on CADD v1.3. The Ensembl VEP tool73 was used for SNP’s primary effect 23 
prediction. 24 
 25 
Co-localization of eGFR and gene expression in cis 26 
As the great majority of gene expression datasets is generated based on EA ancestry 27 
samples, co-localization analysis was based on the genetic associations with eGFR in 28 
the EA sample and with gene expression (eQTL) quantified from micro-dissected human 29 
28 
glomerular and tubulo-interstitial kidney portions from 187 individuals from the NEPTUNE 1 
study,41 as well as from the 44 tissues included in the GTEx Project v6p release.38 The 2 
eQTL and GWAS effect alleles were harmonized. For each locus, we identified tissue 3 
gene pairs with reported eQTL data within ±100 kb of each GWAS index SNP. The region 4 
for each co-localization test was defined as the eQTL cis window defined in the underlying 5 
GTEx and NephQTL studies. We used the ‘coloc.fast’ function, using default setting, from 6 
the R package ‘gtx’ (https://github.com/tobyjohnson/gtx), which is an adaption of 7 
Giambartolomei’s co-localization method.74 ‘gtx’ was also used to estimate the direction 8 
of effect over the credible sets as the ratio of the average PP-weighted GWAS effects 9 
over the PP-weighted eQTL effects.  10 
 11 
Trans-eQTL analysis 12 
We performed trans-eQTL annotation through LD mapping based on the 1000Gp3v5 13 
European reference panel (r2 cut-off >0.8). We limited annotation to replicated index 14 
SNPs with a fine-mapping PP≥1%. Due to expected small effect sizes, only genome-wide 15 
trans-eQTL studies of either peripheral blood mononuclear cells or whole blood with 16 
n≥1000 individuals were considered, resulting in five non-overlapping studies75-79 17 
(Supplementary Table 14). For one study,79 we had access to an update with larger 18 
sample size (n=6645) obtained by combining two non-overlapping studies (LIFE-Heart80 19 
and LIFE-Adult81). To improve stringency of results, we focused the analysis on inter-20 
chromosomal trans-eQTLs with P<5×10-8 in ≥2 studies.  21 
 22 
Co-localization with urinary uromodulin concentrations 23 
Association between concentrations of the urinary uromodulin-to-creatinine ratio with 24 
genetic variants at the UMOD-PDILT locus was evaluated in the German Chronic Kidney 25 
Disease (GCKD) study.82 Uromodulin concentrations were measured from frozen stored 26 
urine using an established ELISA assay with excellent performance.36 Concentrations 27 
were indexed to creatinine to account for urine dilution. Genetic associations were 28 
assessed using the same software and settings as for the eGFR association 29 
29 
(Supplementary Table 2). Co-localization analyses were performed using identical 1 
software and settings as described above for the association with gene expression. 2 
 3 
Life Sciences Reporting Summary 4 
Further information on research methods are available in the Nature Research Life 5 
Sciences Reporting Summary linked to this article.   6 
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Figure Legends 1 
 2 
Figure 1 – Trans-ethnic GWAS meta-analysis identifies 308 loci associated with 3 
eGFR  4 
Circos plot: Red band: –log10(P) for association with eGFR, by chromosomal position. 5 
Blue line indicates genome-wide significance (P=5×10-8). Black gene labels indicate novel 6 
loci, blue labels known loci. Non-replicating loci are colored in gray (novel) or light blue 7 
(known). Green band: Measures of heterogeneity related to the index SNPs associated 8 
with eGFR. Dot sizes are proportional to I² or ancestry-related heterogeneity (p-anc-het). 9 
Blue band: –log10(P) for association with CKD, by chromosomal position. Red line 10 
indicates genome-wide significance (P=5×10-8). Radial lines mark regions with p-anc-het 11 
<1.6×10-4 = 0.05/308 or I² >25%. Inset: Effects of all 308 index SNPs on log(eGFR) by 12 
minor allele frequency, color-coded by the associated odds ratio (OR) of CKD (red scale 13 
for OR≤1, blue scale for OR>1). The largest effects on CKD were observed for 14 
rs77924615 at UMOD-PDILT (odds ratio (OR) = 0.81, 95%CI: 0.80, 0.83), rs187355703 15 
at HOXD8 (OR=0.82, 95%CI: 0.77, 0.87), and rs10254101 at PRKAG2 (OR=1.11, 16 
95%CI: 1.09, 1.11). Triangles highlight SNPs that were associated with CKD (one-sided 17 
P<0.05). 18 
 19 
Figure 2 – Generalizability with respect to other populations and other kidney 20 
function markers 21 
Panel A: Measures of heterogeneity for 308 eGFR-associated index SNPs. 22 
Comparison of each variant’s heterogeneity quantified as I² from the trans-ethnic meta-23 
analysis (Y-axis) vs. ancestry-related heterogeneity from meta-regression (-log10(p-anc-24 
het), X-axis). Histograms summarize the distribution of the heterogeneity measures on 25 
both axes. SNPs with ancestry-related heterogeneity (p-anc-het<1.6×10-4 = 0.05/308) are 26 
marked in blue and labeled; SNPs with I²>50% are labeled. Panel B: Comparison of 27 
genetic effect estimates between CKDGen Consortium discovery (X-axis) and MVP 28 
replication (Y-axis). Blue font indicates one-sided P<0.05 in the MVP. Error bars indicate 29 
37 
95% confidence intervals (CIs). Dashed line: line of best fit. Pearson’s correlation 1 
coefficient r=0.92, 95%CI: 0.90, 0.94. Panel C: Comparison of the magnitude of 2 
genetic effects on eGFR (X-axis) vs. BUN (Y-axis). for the 264 replicated eGFR-3 
associated index SNPs. Color coding reflects the evidence of kidney-function relevance 4 
(see Methods), which is coded as likely (blue), inconclusive (gray), or unlikely (green). 5 
Error bars indicate 95% CIs. Dashed line: line of best fit. Correlation: r=-0.65, 95%CI: -6 
0.72, -0.58. Panel D: Association between lower genetically-predicted eGFR based 7 
on a genetic risk score (GRS) of 147 SNPs likely to be most relevant for kidney 8 
function and ICD-10 based clinical diagnoses from 452,264 individuals from the UK 9 
Biobank. Asthma was included as a negative control. Displayed are odds ratios and their 10 
95% CIs per 10% lower GRS-predicted eGFR (Methods).  11 
 12 
Figure 3 – Human orthologs of genes with renal phenotypes in genetically 13 
manipulated mice are enriched for association signals with eGFR 14 
Signals in candidate genes identified based on the murine phenotypes abnormal GFR 15 
(Panel A), abnormal kidney physiology (Panel B), and abnormal kidney morphology 16 
(Panel C). Y-axis: –log10(P) for association with eGFR in the trans-ethnic meta-analysis 17 
for the variant with the lowest p-value in each candidate gene. Dashed line indicates 18 
genome-wide significance (P=5×10-8), solid gray line indicates the experiment-wide 19 
significance threshold for each nested candidate gene analysis (included in lower right 20 
corner in each panel). Orange color indicates genome-wide significance, red color 21 
experiment-wide but not genome-wide significance, and blue color indicates genes with 22 
no significantly associated SNPs. Genes are labeled when reaching experiment- but not 23 
genome-wide significance; black font for genes not mapping into loci reported in the main 24 
analysis, gray font otherwise. Enrichment p-value reported for observed number of genes 25 
with association signals below the experiment-wide threshold against the expected 26 
number based on the complementary cumulative binomial distribution (Methods). 27 
 28 
Figure 4 – Credible set size (X-axis) against variant posterior probability (Y-axis) of 29 
3655 SNPs in 253 99% credible sets by annotation 30 
38 
Panel A: Exonic variants. SNPs are marked by triangles, with size proportional to their 1 
CADD score. Red triangles and variant labeling indicate missense SNPs mapping into 2 
small (≤5 SNPs) credible sets or with high individual posterior probability of driving the 3 
association signal (>0.5). Panel B: Regulatory potential. Symbol colors identify variants 4 
with regulatory potential as derived from DNAse hypersensitivity analysis in target tissues 5 
(Methods). Variant annotation was restricted to variants with variant PP>1%; SNPs with 6 
PP≥90% contained in credible sets with ≤10 SNPs were labeled. 7 
 8 
Figure 5 – Co-localization of eGFR-association signals with gene expression in 9 
kidney tissues 10 
All eGFR loci were tested for co-localization with all eQTLs where the eQTL cis-window 11 
overlapped (±100 kb) the sentinel genetic variants. Genes with ≥1 positive co-localization 12 
(posterior probability of one common causal variant, H4, ≥0.80) in a kidney tissue are 13 
illustrated with the respective sentinel SNP (Y-axis). Co-localizations across all tissues 14 
(X-axis) are illustrated as dots, where the size of the dots indicates the posterior 15 
probability of the co-localization. Negative co-localizations (posterior probability of H4 16 
<0.80) are marked in gray, while the positive co-localizations are color-coded based on 17 
the predicted change in expression relative to the allele associated with lower eGFR. 18 
 19 
Figure 6 – Co-localization of independent eGFR-association signals at the UMOD-20 
PDILT locus with urinary uromodulin concentrations supports UMOD as the 21 
effector gene. 22 
Association plots: association –log10(p-value) (Y axis) vs. chromosomal position (X axis). 23 
Approximate conditional analyses among EA individuals support the presence of two 24 
independent eGFR-associated signals (Panel A). The association signal with urinary 25 
uromodulin/creatinine levels looks similar (Panel B); r2=0.93 between rs34882080 and 26 
rs34262842. Co-localization of association with eGFR (upper sub-panel) and urinary 27 
uromodulin/creatinine levels (lower sub-panel) for the independent regions centered on 28 
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UMOD (Panel C) and PDILT (Panel D) support a shared underlying variant in both 1 
regions with high posterior probability.  2 
40 
Table 1 – Genes implicated as causal via identification of missense SNPs with high probability of driving the 
eGFR association signal. Genes are included if they contain a missense SNP with posterior probability of association of 
>50% or mapping into a small credible set (≤5 SNPs). 
Gene SNP1 Credible 
set size  
SNP 
PP2 
Functional 
consequence 
CADD 
score3 
DHS4, 
tissue 
Brief summary of the gene’s function and relevant literature (OMIM entries are indicated as #number) 
CACNA1S rs3850625 1 1.00 p.(Arg1539Cys) 
(NP_000060.2) 
34.0 - Encodes a subunit of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle. Reports of altered expression 
in kidney cancer (PMID 28781648) and after indoxyl sulfate treatment (PMID: 27550174). Rare variants can cause autosomal dominant 
hypokalemic periodic paralysis, type 1 (#170400) or malignant hyperthermia susceptibility (#601887). Common variation at this locus has 
been reported as associated with eGFR in previous GWAS (PMID: 24029420, PMID: 26831199). 
CPS1 rs1047891 1 1.00 p.(Thr1406Asn) 
(NP_001866.2) 
22.1 - Encodes a key mitochondrial enzyme of the urea cycle that catalyzes the synthesis of carbamoyl phosphate from ammonia and 
bicarbonate to remove excess urea. Rare mutations cause autosomal recessive carbamoylphosphate synthetase I deficiency (#237300). 
GWAS locus for eGFR (PMID: 20383146), serum metabolites (PMID: 23378610), and urinary glycine (PMID: 26352407), as well as for many 
other quantitative biomarkers. This variant has been reported to associate with hyperammonemia after valproate therapy (PMID: 
23997965).  
EDEM3 rs78444298 1 1.00 p.(Pro746Ser) 
(NP_079467.3) 
24.6 - The gene product accelerates the glycoprotein ER-associated degradation by proteasomes by catalyzing mannose trimming from 
Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans. This variant has been identified by a previous exome chip association study with eGFR 
(PMID: 27920155). 
KLHDC7A rs11261022 7 0.71 p.(Arg160Ser) 
(NP_689588.2) 
1.1 Roadmap, 
ENCODE 
kidney 
Kelch Domain Containing 7A is a protein coding gene and a paralog of KBTBD11. No specific entry in relation to kidney disease in PubMed.  
RPL3L rs113956264 1 1.00 p.(Val262Met) 
(NP_005052.1) 
27.2 - The gene product shares sequence similarity with ribosomal protein L3. It has a tissue-specific expression pattern, with highest levels in 
skeletal muscle and heart. 
SLC25A45 rs34400381 1 1.00 p.(Arg285Cys) 
(NP_001070709
.2) 
26.0 ENCODE 
kidney 
Belongs to the SLC25 family of mitochondrial carrier proteins and is an orphan transporter. This variant has already been identified in a 
GWAS of symmetric dimethylarginine levels (PMID: 24159190) and in a whole-genome sequence (WGS) analysis of serum creatinine 
(PMID: 25082825). SLC25A45 may play a role in biosynthesis of arginine, which is involved in the synthesis of creatine.  
SLC47A1 rs111653425 1 1.00 p.(Ala465Val) 
(NP_060712.2) 
24.6 - Encodes the multidrug and toxin extrusion protein (MATE1), a transport protein responsible for the secretion of cationic drugs and 
creatinine across brush border membranes. This variant has already been identified in a WGS analysis of serum creatinine from Iceland 
(PMID: 25082825). Rare and common variants in the locus have been identified in exome chip (PMID: 27920155) and in GWAS (PMID: 
20383146) studies of eGFR, respectively. MATE1 knockout (KO) mice show higher levels of serum creatinine and BUN (PMID: 19332510), 
arguing against a sole effect on creatinine transport and supporting an effect on kidney function.  
PPM1J rs34611728 5 0.02 p.(Leu213Phe) 
(NP_005158.5) 
13.1 ENCODE 
kidney 
This gene encodes the serine/threonine protein phosphatase. The variant has been reported in association with eGFR in an exome chip 
association study (PMID: 27920155). 
CERS2 rs267738 5 0.46 p.(Glu115Ala) 
(NP_071358.1) 
32.0 
/ 28.2 
- Encodes Ceramide Synthase 2, which may be involved in sphingolipid synthesis. Changes in ceramides were reported as essential in renal 
Madin-Darby Canine Kidney (MDCK) cell differentiation (PMID: 28515139). CERS2 KO mice show strongly reduced ceramide levels in the 
kidney and develop renal parenchyma abnormalities (PMID: 19801672). This variant has been reported as associated with the rate of 
albuminuria increase in patients with diabetes (PMID: 25238615). 
C9 rs700233 5 0.32 p.(Arg5Trp) 
(NP_001728.1) 
6.6 - Encodes a constituent of the membrane attack complex that plays a key role in the innate and adaptive immune response. Rare mutations 
can cause C9 deficiency (#613825). C9 is mentioned in several kidney disease case reports, including patients with congenital factor 9 
deficiency showing IgA nephropathy (PMID: 1453611).  
SLC22A2 rs316019 4 0.04 p.(Ser270Ala) 
(NP_003049.2) 
12.7 - Encodes the polyspecific organic cation transporter (OCT2) that is primarily expressed in the kidney, where it mediates tubular uptake of 
organic compounds including creatinine from the circulation. Many publications relate SLC22A2 to kidney function. rs316019 is a known 
pharmacogenomics variant associated with response to metformin and other drugs such as cisplatin. Carriers of the risk allele have a higher 
risk of cisplatin-induced nephrotoxicity (PMID: 19625999), indicating that this transporter is essential in excreting toxins. The locus has been 
reported in previous GWAS of eGFR (PMID: 20383146). 
1Boldface indicates SNPs most likely to be relevant for kidney function based on the combined effects on eGFR and BUN;  2PP: posterior probability. 3CADD score: Combined Annotation Dependent 
Depletion (CADD) PHRED-like score (Methods); 4DHS: DNAse Hypersensitivity Site
41 
Author List 
Matthias Wuttke*1,2, Yong Li*1, Man Li*3, Karsten B. Sieber*4, Mary F. Feitosa*5, Mathias 
Gorski*6,7, Adrienne Tin8,9, Lihua Wang5, Audrey Y. Chu10, Anselm Hoppmann1, Holger 
Kirsten11,12, Ayush Giri13,14, Jin-Fang Chai15, Gardar Sveinbjornsson16, Bamidele O. 
Tayo17, Teresa Nutile18, Christian Fuchsberger19, Jonathan Marten20, Massimiliano 
Cocca21, Sahar Ghasemi22,23, Yizhe Xu3, Katrin Horn11,12, Damia Noce19, Peter J. van der 
Most24, Sanaz Sedaghat25, Zhi Yu8,26, Masato Akiyama27,28, Saima Afaq29,30, Tarunveer 
S. Ahluwalia31, Peter Almgren32, Najaf Amin25, Johan Ärnlöv33,34, Stephan J.L. Bakker35, 
Nisha Bansal36,37, Daniela Baptista38, Sven Bergmann39,40,41, Mary L. Biggs42,43, Ginevra 
Biino44, Michael Boehnke45, Eric Boerwinkle46, Mathilde Boissel47, Erwin P. Bottinger48,49, 
Thibaud S. Boutin20, Hermann Brenner50,51, Marco Brumat52, Ralph Burkhardt12,53,54, 
Adam S. Butterworth55,56, Eric Campana52, Archie Campbell57, Harry Campbell58, Mickaël 
Canouil47, Robert J. Carroll59, Eulalia Catamo21, John C. Chambers29,60,61,62,275, Miao-Ling 
Chee63, Miao-Li Chee63, Xu Chen64, Ching-Yu Cheng63,65,66, Yurong Cheng1, Kaare 
Christensen67, Renata Cifkova68,69, Marina Ciullo18,70, Maria Pina Concas21, James P. 
Cook71, Josef Coresh8, Tanguy Corre39,40,72, Sala Cinzia Felicita73, Daniele Cusi74,75, John 
Danesh76, E. Warwick Daw5, Martin H. de Borst35, Alessandro De Grandi19, Renée de 
Mutsert77, Aiko P.J. de Vries78, Frauke Degenhardt79, Graciela Delgado80, Ayse 
Demirkan25, Emanuele di Angelantonio81,82,83, Katalin Dittrich84,85, Jasmin Divers86, 
Rajkumar Dorajoo87, Kai-Uwe Eckardt88,89, Georg Ehret38, Paul Elliott90,91,92,93, Karlhans 
Endlich23,94, Michele K. Evans95, Janine F. Felix25,96,97, Valencia Hui Xian Foo63, Oscar H. 
Franco25,98, Andre Franke79, Barry I. Freedman99, Sandra Freitag-Wolf100, Yechiel 
Friedlander101, Philippe Froguel47,102, Ron T. Gansevoort35, He Gao90, Paolo 
Gasparini21,52, J. Michael Gaziano103, Vilmantas Giedraitis104, Christian Gieger105,106,107, 
Giorgia Girotto21,52, Franco Giulianini108, Martin Gögele19, Scott D. Gordon109, Daniel F. 
Gudbjartsson16, Vilmundur Gudnason110,111, Toomas Haller112, Pavel Hamet113,114, 
Tamara B. Harris115, Catharina A. Hartman116, Caroline Hayward20, Jacklyn N. 
Hellwege117,118,119, Chew-Kiat Heng120,121, Andrew A. Hicks19, Edith Hofer122,123, Wei 
Huang124,125, Nina Hutri-Kähönen126,127, Shih-Jen Hwang128,129, M. Arfan Ikram25, Olafur 
S. Indridason130, Erik Ingelsson131,132,133,134, Marcus Ising135, Vincent W.V. Jaddoe25,96,97, 
Johanna Jakobsdottir136,137, Jost B. Jonas138,139, Peter K. Joshi58, Navya Shilpa 
Josyula140, Bettina Jung6, Mika Kähönen141,142, Yoichiro Kamatani27,143, Candace M. 
Kammerer144, Masahiro Kanai27,145, Mika Kastarinen146, Shona M. Kerr20, Chiea-Chuen 
Khor63,87, Wieland Kiess12,84,85, Marcus E. Kleber80, Wolfgang Koenig147,148,149, Jaspal S. 
Kooner61,62,150,151, Antje Körner12,84,85, Peter Kovacs152, Aldi T. Kraja5, Alena 
Krajcoviechova68,69, Holly Kramer17,153, Bernhard K. Krämer80, Florian Kronenberg154, 
Michiaki Kubo155, Brigitte Kühnel105, Mikko Kuokkanen156,157, Johanna Kuusisto158,159, 
Martina La Bianca21, Markku Laakso158,159, Leslie A. Lange160, Carl D. Langefeld86, 
Jeannette Jen-Mai Lee15, Benjamin Lehne29, Terho Lehtimäki161,162, Wolfgang Lieb163, 
Lifelines Cohort Study164, Su-Chi Lim15,165, Lars Lind166, Cecilia M. Lindgren167,168, Jun 
Liu25, Jianjun Liu87,169, Markus Loeffler11,12, Ruth J.F. Loos48,170, Susanne Lucae135, Mary 
Ann Lukas171, Leo-Pekka Lyytikäinen161,162, Reedik Mägi112, Patrik K.E. Magnusson64, 
Anubha Mahajan172,173, Nicholas G. Martin109, Jade Martins174, Winfried März175,176,177, 
Deborah Mascalzoni19, Koichi Matsuda178, Christa Meisinger179,180, Thomas 
Meitinger148,181,182, Olle Melander183, Andres Metspalu112, Evgenia K. Mikaelsdottir16, Yuri 
Milaneschi184, Kozeta Miliku25,96,97, Pashupati P. Mishra161,162, VA Million Veteran 
42 
Program185, Karen L. Mohlke186, Nina Mononen161,162, Grant W. Montgomery187, Dennis 
O. Mook-Kanamori77,188, Josyf C. Mychaleckyj189, Girish N. Nadkarni48,190, Mike A. 
Nalls191,192, Matthias Nauck23,193, Kjell Nikus194,195, Boting Ning196, Ilja M. Nolte24, 
Raymond Noordam197, Jeffrey O'Connell198, Michelle L. O'Donoghue199,200, Isleifur 
Olafsson201, Albertine J. Oldehinkel116, Marju Orho-Melander32, Willem H. Ouwehand76, 
Sandosh Padmanabhan202, Nicholette D. Palmer203, Runolfur Palsson111,130, Brenda 
W.J.H. Penninx184, Thomas Perls204, Markus Perola205,206, Mario Pirastu207, Nicola 
Pirastu58, Giorgio Pistis208, Anna I. Podgornaia10, Ozren Polasek209,210, Belen Ponte211, 
David J. Porteous57,212, Tanja Poulain12, Peter P. Pramstaller19, Michael H. Preuss48, 
Bram P. Prins55, Michael A. Province5, Ton J. Rabelink78,213, Laura M. Raffield186, Olli T. 
Raitakari214,215, Dermot F. Reilly10, Rainer Rettig216, Myriam Rheinberger6, Kenneth M. 
Rice43, Paul M. Ridker108,217, Fernando Rivadeneira25,218, Federica Rizzi219,220, David J. 
Roberts81,221, Antonietta Robino21, Peter Rossing31, Igor Rudan58, Rico Rueedi39,40, 
Daniela Ruggiero18,70, Kathleen A. Ryan222, Yasaman Saba223, Charumathi 
Sabanayagam63,224, Veikko Salomaa205, Erika Salvi219,225, Kai-Uwe Saum50, Helena 
Schmidt226, Reinhold Schmidt122, Ben Schöttker50,51, Christina-Alexandra Schulz32, Nicole 
Schupf227,228,229, Christian M. Shaffer59, Yuan Shi63,224, Albert V. Smith111, Blair H. 
Smith230, Nicole Soranzo231, Cassandra N. Spracklen186, Konstantin Strauch232,233, 
Heather M. Stringham45, Michael Stumvoll234, Per O. Svensson235,236, Silke Szymczak100, 
E-Shyong Tai15,169,237, Salman M. Tajuddin95, Nicholas Y. Q. Tan63, Kent D. Taylor238, 
Andrej Teren12,239, Yih-Chung Tham63, Joachim Thiery12,53, Chris H.L. Thio24, Hauke 
Thomsen240, Gudmar Thorleifsson16, Daniela Toniolo73, Anke Tönjes234, Johanne 
Tremblay113,241, Ioanna Tzoulaki90,242, André G. Uitterlinden218, Simona Vaccargiu207, Rob 
M. van Dam15,169,243, Pim van der Harst244,245,246, Cornelia M. van Duijn25, Digna R. Velez 
Edward119,247,248, Niek Verweij244, Suzanne Vogelezang25,96,97, Uwe Völker23,249, Peter 
Vollenweider250, Gerard Waeber250, Melanie Waldenberger105,106,148, Lars Wallentin251,252, 
Ya Xing Wang139, Chaolong Wang87,253, Dawn M. Waterworth4, Wen Bin Wei254, Harvey 
White255, John B. Whitfield109, Sarah H. Wild256, James F. Wilson20,58, Mary K. 
Wojczynski5, Charlene Wong66, Tien-Yin Wong63,66,224, Liang Xu139, Qiong Yang196, 
Masayuki Yasuda63,257, Laura M. Yerges-Armstrong4, Weihua Zhang61,90, Alan B. 
Zonderman95, Jerome I. Rotter238,258,259, Murielle Bochud72, Bruce M. Psaty260,261, 
Veronique Vitart20, James G. Wilson262, Abbas Dehghan29,90, Afshin Parsa263,264, Daniel 
I. Chasman108,217, Kevin Ho265,266, Andrew P. Morris71,172, Olivier Devuyst267, Shreeram 
Akilesh37,268, Sarah A. Pendergrass269, Xueling Sim15, Carsten A. Böger6,270, Yukinori 
Okada271,272, Todd L. Edwards119,273, Harold Snieder24, Kari Stefansson16, Adriana M. 
Hung119,274, Iris M. Heid**7, Markus Scholz**11,12, Alexander Teumer**22,23, Anna 
Köttgen**†1,8, Cristian Pattaro**†19 
 
* Indicates joint contribution 
** Indicates joint oversight 
† Indicates corresponding author  
43 
Author affiliations 
1 Institute of Genetic Epidemiology, Department of Biometry, Epidemiology and Medical Bioinformatics, Faculty of Medicine and 
Medical Center - University of Freiburg, Freiburg, Germany 
2 Department of Medicine IV, Renal Division, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany 
3 Department of Medicine, Division of Nephrology and Hypertension, University of Utah, Salt Lake City, USA 
4 Target Sciences - Genetics, GlaxoSmithKline, Collegeville (Pennsylvania), USA 
5 Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis (Missouri), USA 
6 Department of Nephrology, University Hospital Regensburg, Regensburg, Germany 
7 Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany 
8 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore (Maryland), USA 
9 Epidemiology and Clinical Research, Welch Centre for Prevention, Baltimore (Maryland), USA 
10 Genetics, Merck & Co., Inc., Kenilworth, New Jersey, USA 
11 Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany 
12 LIFE Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany 
13 Division of Quantitative Sciences, Department of Obstetrics & Gynecology, Vanderbilt Genetics Institute, Vanderbilt 
Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA 
14 Biomedical Laboratory Research and Development, Tennessee Valley Healthcare System (626)/Vanderbilt University, Nashville, 
TN, USA 
15 Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, 
Singapore 
16 deCODE Genetics, Amgen Inc., Reykjavik, Iceland 
17 Department of Public Health Sciences, Loyola University Chicago, Maywood (Illinois), USA 
18 Institute of Genetics and Biophysics "Adriano Buzzati-Traverso" - CNR, Naples, Italy 
19 Eurac Research, Institute for Biomedicine (affiliated to the University of Lübeck), Bolzano, Italy 
20 Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, 
Edinburgh, UK 
21 Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy 
22 Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany 
23 DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany 
24 Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 
25 Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 
26 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore (Maryland), USA 
27 Laboratory for Statistical Analysis, RIKEN Centre for Integrative Medical Sciences (IMS), Yokohama (Kanagawa), Japan 
28 Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 
29 Department of Epidemiology and Biostatistics, Faculty of Medicine, School of Public Health, Imperial College London, London, 
UK 
30 Institute of Public health & social sciences, Khyber Medical University, Pakistan 
31 Steno Diabetes Centre Copenhagen, Gentofte, Denmark 
32 Diabetes and Cardiovascular Disease - Genetic Epidemiology, Department of Clincial Sciences in Malmö, Lund University, 
Malmö, Sweden 
33 Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, 
Stockholm, Sweden 
34 School of Health and Social Studies, Dalarna University, Sweden 
35 Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, 
Groningen, The Netherlands 
36 Division of Nephrology, University of Washington, Seattle (Washington), USA 
37 Kidney Research Institute, University of Washington, Seattle (Washington), USA 
38 Cardiology, Geneva University Hospitals, Geneva, Switzerland 
39 Department of Computational Biology, University of Lausanne, Lausanne, Switzerland 
40 Swiss Institute of Bioinformatics, Lausanne, Switzerland 
41 Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa 
42 Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle (Washington), USA 
43 Department of Biostatistics, University of Washington, Seattle (Washington), USA 
44 Institute of Molecular Genetics, National Research Council of Italy, Pavia, Italy 
45 Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA 
46 Human Genetics Centre, University of Texas Health Science Centre, Houston (Texas), USA 
47 CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille, France 
48 The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York (New York), USA 
49 Digital Health Centre, Hasso Plattner Institute and University of Potsdam, Potsdam, Germany 
50 Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre (DKFZ), Heidelberg, Germany 
51 Network Aging Research, University of Heidelberg, Heidelberg, Germany 
52 University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy 
53 Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany 
54 Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany 
55 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, 
Cambridge, UK 
56 National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of 
Cambridge, Cambridge, UK 
57 Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, 
44 
Edinburgh, UK 
58 Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, 
Edinburgh, UK 
59 Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville (Tennessee), USA 
60 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore 
61 Department of Cardiology, Ealing Hospital, Middlesex UB1 3HW, UK 
62 Imperial College Healthcare NHS Trust, Imperial College London, London, UK 
63 Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore 
64 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 
65 Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore 
66 Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health 
System, Singapore, Singapore 
67 Unit of Epidemiology, Biostatistics and Biodemography, Department of Public Health, Southern Denmark University, Odense, 
Denmark 
68 Centre for Cardiovascular Prevention, First Faculty of Medicine, Department of Medicine, Charles University in Prague, Prague, 
Czech Republic 
69 Thomayer Hospital, Prague, Czech Republic 
70 IRCCS Neuromed, Pozzilli, Italy 
71 Department of Biostatistics, University of Liverpool, Liverpool, UK 
72 Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland 
73 San Raffaele Research Institute, Milano, Italy 
74 Institute of Biomedical Technologies, Italy National Research Council, Bresso (Milano), Italy 
75 Bio4Dreams - business nursery for life sciences, Bresso (Milano), Italy 
76 University of Cambridge, Cambridge, UK 
77 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands 
78 Section of Nephrology, Department of Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands 
79 Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany 
80 5th Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty 
Mannheim, University of Heidelberg, Mannheim, Germany 
81 Blood and Transplant Research Unit in Donor Health and Genomics, National Institute of Health Research, Cambridge, UK 
82 Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK 
83 NHS Blood and Transplant, Cambridge, UK 
84 Department of Women and Child Health, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany 
85 Centre for Pediatric Research, University of Leipzig, Leipzig, Germany 
86 Public Health Sciences - Biostatistics, Wake Forest School of Medicine, Winston-Salem (North Carolina), USA 
87 Genome Institute of Singapore, Agency for Science Technology and Research, Singapore, Singapore 
88 Intensive Care Medicine, Charité, Berlin, Germany 
89 Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany 
90 Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial 
College London, London, UK 
91 Imperial College NIHR Biomedical Research Centre, Imperial College London, London, UK 
92 Dementia Research Institute, Imperial College London, London, UK 
93 Health Data Research UK-London, London, UK 
94 Department of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany 
95 Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National 
Institutes of Health, Baltimore (Maryland), USA 
96 The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 
97 Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 
98 Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland 
99 Internal Medicine - Section on Nephrology, Wake Forest School of Medicine, Winston-Salem (North Carolina), USA 
100 Institute of Medical Informatics and Statistics, Kiel University, University Hospital Schleswig-Holstein, Kiel 
101 School of Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem, Israel 
102 Department of Genomics of Common Disease, Imperial College London, London, UK 
103 Massachusetts Veterans Epidemiology Research and Information Center, VA Cooperative Studies Program, VA Boston 
Healthcare System, Boston (Massachusetts), USA 
104 Department of Public Health and Caring Sciences, Molecular Geriatrics, Uppsala University, Uppsala, Sweden 
105 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health, 
Neuherberg, Germany 
106 Institute of Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health, Neuherberg, 
Germany 
107 German Center for Diabetes Research (DZD), Neuherberg, Germany 
108 Division of Preventive Medicine, Brigham and Women's Hospital, Boston, USA 
109 QIMR Berghofer Medical Research Institute, Brisbane, Australia 
110 Icelandic Heart Association, Kopavogur, Iceland 
111 Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland 
112 Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia 
113 Montreal University Hospital Research Centre, CHUM, Montreal, Canada 
114 Medpharmgene, Montreal, Canada 
115 Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National 
Institutes of Health, Bethesda (Maryland), USA 
45 
116 Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE), University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands 
117 Vanderbilt Genetics Institute, Vanderbilt University Medical Centre, Nashville, USA 
118 Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Centre, USA 
119 Department of Veteran’s Affairs, Tennessee Valley Healthcare System (626)/Vanderbilt University, Nashville, TN, USA 
120 Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 
121 Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore 
122 Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria 
123 Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria 
124 Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome 
Centre, Shanghai, China 
125 Shanghai Industrial Technology Institute, Shanghai, China 
126 Department of Pediatrics, Tampere University Hospital, Tampere, Finland 
127 Department of Pediatrics, Faculty of Medicine and Life Sciences, University of Tampere, Finland 
128 NHLBI's Framingham Heart Study, Framingham (Massachusetts), USA 
129 The Centre for Population Studies, NHLBI, Framingham (Massachusetts), USA 
130 Division of Nephrology, Internal Medicine Services, Landspitali - he National University Hospital of Iceland, Reykjavik, Iceland 
131 Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, USA 
132 Stanford Cardiovascular Institute, Stanford University, USA 
133 Molecular Epidemiology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, 
Sweden 
134 Stanford Diabetes Research Center, Stanford University, Stanford, USAs 
135 Max Planck Institute of Psychiatry, Munich, Germany 
136 Icelandic Heart Association, Holtasmari 1, Kopavogur IS-201, Iceland 
137 The Centre of Public Health Sciences, University of Iceland, Sturlugata 8, Reykjavík IS-101, Iceland 
138 Department of Ophthalmology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany 
139 Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, 
Capital Medical University, Beijing, China 
140 Geisinger Research, Biomedical and Translational Informatics Institute, Rockville, USA 
141 Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland 
142 Department of Clinical Physiology, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Health 
Technology, Tampere University, Tampere, Finland 
143 Kyoto-McGill International Collaborative School in Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
Japan 
144 Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh (Pennsylvania), USA 
145 Department of Biomedical Informatics, Harvard Medical School, Boston, USA 
146 Kuopio University Hospital, Kuopio, Finland 
147 Deutsches Herzzentrum München, Technische Universität München, Munich, Germany 
148 DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany 
149 Institute of Epidemiology and Biostatistics, University of Ulm, Ulm, Germany 
150 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK 
151 National Heart and Lung Institute, Imperial College London, London, UK 
152 Integrated Research and Treatment Centre Adiposity Diseases, University of Leipzig, Leipzig, Germany 
153 Division of Nephrology and Hypertension, Loyola University Chicago, USA 
154 Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of 
Innsbruck, Innsbruck, Austria 
155 RIKEN Centre for Integrative Medical Sciences (IMS), Yokohama (Kanagawa), Japan 
156 The Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland 
157 Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland 
158 University of Eastern Finland, Kuopio, Finland 
159 Kuopio University Hospital, Finland 
160 Division of Biomedical Informatics and Personalized Medicine, School of Medicine, University of Colorado Denver - Anschutz 
Medical Campus, Aurora (Colorado), USA 
161 Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland 
162 Department of Clinical Chemistry, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, 
University of Tampere, Tampere, Finland 
163 Institute of Epidemiology and Biobank Popgen, Kiel University, Kiel, Germany 
164 A list of members and affiliations appears in the Supplementary Material. 
165 Diabetes Centre, Khoo Teck Puat Hospital, Singapore, Singapore 
166 Cardiovascular Epidemiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden 
167 Nuffield Department of Medicine, University of Oxford, Oxford, UK 
168 Broad Institute of Harvard and MIT, USA 
169 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health 
System, Singapore, Singapore 
170 The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York (New York), USA 
171 Target Sciences - Genetics, GlaxoSmithKline, Albuquerque (New Mexico), USA 
172 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK 
173 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK 
174 Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany 
175 Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany 
46 
176 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria 
177 Medical Clinic V, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany 
178 Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan 
179 Independent Research Group Clinical Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental 
Health, Neuherberg, Germany 
180 Chair of Epidemiology Ludwig- Maximilians-Universität München at UNIKA-T Augsburg, Augsburg, Germany 
181 Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany 
182 Institute of Human Genetics, Technische Universität München, Munich, Germany 
183 Hypertension and Cardiovascular Disease, Department of Clincial Sciences Malmö, Lund University, Malmö, Sweden 
184 Department of Psychiatry, VU University Medical Centre, Amsterdam, The Netherlands 
185 Department of Veterans Affairs. Office of Research and Development, Washington, DC, USA. A list of members and affiliations 
appears in the Supplementary Material. 
186 Department of Genetics, University of North Carolina, Chapel Hill (North Carolina), USA 
187 University of Queensland, St Lucia, Australia 
188 Department of Public Health and Primary Care, Leiden University Medical Centre, Leiden, The Netherlands 
189 Centre for Public Health Genomics, University of Virginia, Charlottesville (Virginia), USA 
190 Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York (New York), USA 
191 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda (Maryland), USA 
192 Data Tecnica International, Glen Echo (Maryland), USA 
193 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany 
194 Department of Cardiology, Heart Center, Tampere University Hospital, Tampere, Finland 
195 Department of Cardiology, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, 
Tampere University, Tampere, Finland 
196 Department of Biostatistics, Boston University School of Public Health, Boston (Massachusetts), USA 
197 Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Centre, Leiden, The 
Netherlands 
198 University of Maryland School of Medicine, Baltimore, USA 
199 Cardiovascular Division, Brigham and Women's Hospital, Boston, USA 
200 TIMI Study Group, USA 
201 Department of Clinical Biochemistry, Landspitali University Hospital, Reykjavik, Iceland 
202 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK 
203 Biochemistry, Wake Forest School of Medicine, Winston-Salem (North Carolina), USA 
204 Department of Medicine, Geriatrics Section, Boston Medical Center, Boston University School of Medicine, Boston 
(Massachusetts), USA 
205 National Institute for Health and Welfare, Helsinki, Finland 
206 The Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland 
207 Institute of Genetic and Biomedical Research, National Research Council of Italy, UOS of Sassari, Li Punti (Sassari), Italy 
208 Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland 
209 Faculty of Medicine, University of Split, Split, Croatia 
210 Gen-info Ltd, Zagreb, Croatia 
211 Service de Néphrologie, Geneva University Hospitals, Geneva, Switzerland 
212 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK 
213 Einthoven Laboratory of Experimental Vascular Research, Leiden University Medical Centre, Leiden, The Netherlands 
214 Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland 
215 Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland 
216 Institute of Physiology, University Medicine Greifswald, Karlsburg, Germany 
217 Harvard Medical School, USA 
218 Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 
219 Department of Health Sciences, University of Milan, Milano, Italy 
220 ePhood Scientific Unit, ePhood SRL, Milano, Italy 
221 NHS Blood and Transplant; BRC Oxford Haematology Theme; Nuffield Division of Clinical Laboratory Sciences; University of 
Oxford, Oxford, UK 
222 Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA 
223 Molecular Biology and Biochemistry, Gottfried Schatz Research Centre for Cell Signaling, Metabolism and Aging, Medical 
University of Graz, Graz, Austria 
224 Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore 
225 Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy 
226 Institute of Molecular Biology and Biochemistry, Centre for Molecular Medicine, Medical University of Graz, Graz, Austria 
227 Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, USA 
228 Gertrude H. Sergievsky Centre, Columbia University Medical Centre, USA 
229 Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Centre, New York, USA 
230 Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK 
231 Wellcome Sanger Institute, South Cambridgeshire, UK 
232 Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health, 
Neuherberg, Germany 
233 Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany 
234 Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany 
235 Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset (KI SÖS), Stockholm, Sweden 
236 Department of Cardiology, Södersjukhuset, Stockholm, Sweden 
237 Duke-NUS Medical School, Singapore, Singapore 
47 
238 The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Los Angeles Biomedical Research 
Institute at Harbor-UCLA Medical Center, Torrance, CA, USA 
239 Heart Centre Leipzig, Leipzig, Germany 
240 Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany 
241 CRCHUM, Montreal, Canada 
242 Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece 
243 Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA 
244 Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 
245 Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 
246 Durrer Centre for Cardiovascular Research, The Netherlands Heart Institute, Utrecht, The Netherlands 
247 Department of Obstetrics and Gynecology, Institute for Medicine and Public Health, Vanderbilt University Medical Centre, 
Nashville (TN), USA 
248 Vanderbilt Genetics Institute, Vanderbilt University Medical Centre, USA 
249 Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany 
250 Internal Medicine, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland 
251 Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden 
252 Uppsala Clinical Research Centre, Uppsala University. Uppsala, Sweden 
253 School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 
254 Beijing Tongren Eye Centre, Beijing Tongren Hospital, Capital Medical University, Beijing, China 
255 Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand 
256 Centre for Population Health Sciences, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, 
Edinburgh, UK 
257 Department of Ophthalmology, Tohoku University Graduate School of Medicine, Japan 
258 Department of Pediatrics, Harbor-UCLA Medical Centre, USA 
259 Department of Medicine, Harbor-UCLA Medical Centre, Torrance, USA 
260 Cardiovascular Health Research Unit, Department of Medicine, Department of Epidemiology, Department of Health Service, 
University of Washington, Seattle (Washington), USA 
261 Kaiser Permanente Washington Health Research Institute, Seattle (Washington), USA 
262 Department of Physiology and Biophysics, University of Mississippi Medical Centre, Jackson (Mississippi), USA 
263 Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, 
National Institutes of Health, Bethesda, USA 
264 Department of Medicine, University of Maryland School of Medicine, Baltimore, USA 
265 Kidney Health Research Institute (KHRI), Geisinger, Danville (Pennsylvania), USA 
266 Department of Nephrology, Geisinger, Danville (Pennsylvania), USA 
267 Institute of Physiology, University of Zurich, Zurich, Switzerland 
268 Anatomic Pathology, University of Washington Medical Center, Seattle, USA 
269 Geisinger Research, Biomedical and Translational Informatics Institute, Danville (Pennsylvania), USA 
270 Department of Nephrology and Rheumatology, Kliniken Südostbayern AG, Regensburg, Germany 
271 Laboratory for Statistical Analysis, RIKEN Centre for Integrative Medical Sciences (IMS), Osaka, Japan 
272 Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan 
273 Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Centre, 
Nashville, TN, USA 
274 Vanderbilt University Medical Centre, Division of Nephrology & Hypertension, Nashville, TN, USA  
275 MRC-PHE Centre for Environment and Health, Imperial College London, London W2 1PG, UK  
